Welcome to our dedicated page for AirSculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on AirSculpt Technologies stock.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) is an innovative leader in the body contouring industry, delivering premium cosmetic procedures under its renowned brand, Elite Body Sculpture. Utilizing its patented AirSculpt® technology, the company offers minimally invasive procedures that remove unwanted fat, tighten skin, and sculpt targeted areas of the body. These procedures are designed for quick healing with minimal bruising, making them highly sought after among patients looking for effective and efficient results.
Established in 2012, AirSculpt has expanded its reach with over 27 state-of-the-art facilities across the United States, Canada, and the United Kingdom. Recent expansions include the redesign of its Scottsdale location and the relocation of its Atlanta office to cater to the growing demand for its services. The company has continually innovated, recently introducing the AirSculpt® Lift for facial rejuvenation and AirSculpt®+ for enhanced skin tightening, further solidifying its position in the market.
Financially, AirSculpt has shown robust growth, reporting a significant increase in both revenue and case volume. In the third quarter of 2023, the company saw a 20.3% rise in revenue, amounting to $46.8 million, and a 19% increase in case volume to 3,426 cases. Despite facing macroeconomic challenges, the company's strategic investments in new locations and customer acquisition have continued to drive its performance. AirSculpt's financial health is further strengthened by a positive cash flow and a solid balance sheet, with $11.0 million in cash and equivalents as of March 31, 2024.
A key aspect of AirSculpt's success is its commitment to providing an unmatched patient experience. The company's procedures are not only effective but also comfortable, with patients remaining awake during the process. Partnerships with influencers and celebrities, like Kristen Doute from Bravo's The Valley, have enhanced the company's visibility and credibility, attracting a broader audience.
Looking forward, AirSculpt remains dedicated to expanding its footprint with plans to open six new centers in 2024. The company's outlook projects continued revenue growth and increased adjusted EBITDA, demonstrating confidence in its ability to scale and meet the rising demand for body contouring services. AirSculpt Technologies uses its website as a primary channel for disseminating important company information and engages regularly with investors through conference calls and updates.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) has announced a new credit agreement with lenders, securing $85 million in term loans and a $5 million revolving loan facility. This funding will pay off an existing $83.6 million credit facility due October 28, 2023. The new agreement, maturing on November 7, 2027, is expected to save the company approximately $2 million annually in cash interest, with no prepayment penalties. CFO Dennis Dean expressed satisfaction with the refinancing, noting it provides flexibility to pursue strategic growth plans.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) has announced the opening of its new centers in Philadelphia and Boston, bringing the total to 21 locations across the U.S. The company specializes in premium body contouring procedures utilizing its proprietary AirSculpt technology, known for its minimally invasive approach that facilitates faster healing and more precise results. Over 30,000 procedures have been conducted nationally, indicating a robust demand for their services. The Boston center opened in July, while the Philadelphia center is centrally located near King of Prussia Mall.
AirSculpt Technologies (NASDAQ: AIRS) has announced that it will release its third quarter results on November 10, 2022, after market close. Following this, a conference call will be held on November 11, 2022, at 8:30 AM ET for investors and the public to discuss the results. Access to the call is available via phone or through a webcast on the company's investor relations website. AirSculpt is known for its proprietary AirSculpt® method, which offers a minimally invasive body contouring procedure aiming to deliver significant results for patients.
AirSculpt Technologies (NASDAQ: AIRS) announced management's participation at the Piper Sandler Growth Frontiers Conference in Nashville, TN on September 13, 2022. The event will include 1x1 investor meetings and a fireside chat at 5:00 PM ET. A live webcast and replay will be accessible on AirSculpt's investor relations site.
AirSculpt specializes in premium body contouring procedures, using its proprietary AirSculpt® method for minimally invasive fat removal, aiming to deliver exceptional results for patients.
AirSculpt Technologies (NASDAQ: AIRS) has introduced AirSculpt Smooth, a new cellulite removal procedure that is FDA-cleared and minimally invasive. This one-time procedure offers complete removal of stubborn cellulite dimples and is designed to be performed alongside AirSculpt's fat removal method. Clients can expect to resume normal activities within 24-48 hours. The procedure utilizes the Aveli device from Revelle Aesthetics and aims to provide lasting results that improve over three months, enhancing the body contouring experience.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) reported a strong second quarter for 2022, with a 42% year-over-year revenue increase to $49.7 million. The company declared a $0.41 per share special cash dividend, payable on September 14, 2022. Despite revenue growth, net income fell to $0.6 million, impacted by rising equity-based compensation and public company costs. Year-to-date results show a 46% revenue increase to $89.2 million. The company maintains a revenue outlook of $175-$179 million for 2022 and aims to open four new centers annually.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) announced a special cash dividend of $0.41 per share to be paid on September 14, 2022, for shareholders on record as of August 26, 2022. This decision reflects the Board of Directors' confidence in the company's long-term growth potential and strong financial position, as stated by Chairman Adam Feinstein. The dividend will be funded by excess cash from operations, while ensuring continued financial flexibility for future business growth.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) announced the release of its second quarter results, scheduled for August 12, 2022, before market open. Following the results, a conference call will occur at 8:30 a.m. Eastern Time, accessible by phone or a webcast on the company's investor relations page. AirSculpt is known for its premium body contouring procedures using the proprietary AirSculpt® method, which offers minimally invasive fat removal. The company continues to focus on delivering the best results for its patients.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) reported a robust first quarter for 2022, with cases increasing by 31.1% to 3,156, and revenue soaring by 51.3% to $39.5 million. The company noted significant growth in same-center metrics, with cases up 12.2% and revenue per case up 14.6%. However, a net loss of $(0.7) million was reported, compared to a net income of $6.6 million last year. Adjusted EBITDA slightly increased to $9.8 million. The company has raised its full-year revenue outlook to between $175-$179 million.
AirSculpt Technologies (NASDAQ: AIRS) will announce its first quarter results on May 13, 2022, before the market opens. A conference call will follow at 8:30 a.m. Eastern Time, accessible via phone or webcast. Investors can participate by calling 1-877-407-9716 for US calls, or 1-201-493-6779 for international calls. A replay will be available shortly after the call. AirSculpt specializes in body contouring procedures under the Elite Body Sculpture brand, utilizing their proprietary AirSculpt® method for effective fat removal.
FAQ
What is the current stock price of AirSculpt Technologies (AIRS)?
What is the market cap of AirSculpt Technologies (AIRS)?
What does AirSculpt Technologies, Inc. specialize in?
Where are AirSculpt's procedures available?
What recent innovations has AirSculpt introduced?
How has AirSculpt performed financially?
What are AirSculpt's future plans?
Who are some notable clients of AirSculpt?
How does AirSculpt ensure a premium patient experience?
What are the benefits of AirSculpt® technology?
How does AirSculpt keep investors informed?
What is AirSculpt's approach to growth and expansion?
